Table 6.
Therapy of the PNM, including AET and ADT
| Therapy | AP(929) | Non-AP(261) | Total(1190) | P |
|---|---|---|---|---|
| AET | 851 (91.6%) | 231 (88.5%) | 1082 (90.9%) | 0.143 |
| Meropenem | 53 (6.2%) | 12 (5.2%) | 65 (6.0%) | 0.641 |
| Ceftazidime | 63 (7.4%) | 26 (11.3%) | 89 (8.2%) | 0.078 |
| Cefotaxime | 18 (2.1%) | 6 (2.6%) | 24 (2.2%) | 0.619 |
| Ceftriaxone | 81 (9.5%) | 17 (7.4%) | 98 (9.1%) | 0.366 |
| Vancomycin | 26 (3.1%) | 9 (3.9%) | 35 (3.2%) | 0.530 |
| Meropenem + Vancomycin | 389 (45.7%) | 90 (39.0%) | 479 (44.3%) | 0.073 |
| Ceftazidime + Vancomycin | 29 (3.4%) | 12 (5.2%) | 41 (3.8%) | 0.242 |
| Ceftriaxone + Vancomycin | 18 (2.1%) | 8 (3.5%) | 26 (2.4%) | 0.231 |
| Cefotaxime + Vancomycin | 27 (3.2%) | 12 (5.2%) | 39 (3.6%) | 0.162 |
| Sulbactam Sodium + Meropenem + Vancomycin | 12 (1.4%) | 6 (2.6%) | 18 (1.7%) | 0.234 |
| Others | 135 (15.9%) | 33 (14.3%) | 168 (15.5%) | 0.609 |
| ADT | 776 (83.5%) | 213 (81.6%) | 989 (83.1%) | 0.456 |
| Meropenem | 57 (7.3%) | 15 (7.0%) | 72 (7.3%) | 0.999 |
| Ceftazidime | 23 (3.0%) | 15 (7.0%) | 38 (3.8%) | 0.014 |
| Cefotaxime | 11 (1.4%) | 4 (1.9%) | 15 (1.5%) | 0.542 |
| Ceftriaxone | 22 (2.8%) | 7 (3.3%) | 29 (2.9%) | 0.654 |
| Vancomycin | 30 (3.9%) | 8 (3.8%) | 38 (3.8%) | 0.999 |
| Meropenem + Vancomycin | 370 (47.7%) | 96 (45.1%) | 466 (47.1%) | 0.536 |
| Ceftazidime + Vancomycin | 12 (1.5%) | 6 (2.8%) | 18 (1.8%) | 0.245 |
| Ceftriaxone + Vancomycin | 12 (1.5%) | 3 (1.4%) | 15 (1.5%) | 0.999 |
| Cefotaxime + Vancomycin | 14 (1.8%) | 5 (2.3%) | 19 (1.9%) | 0.578 |
| Sulbactam Sodium + Meropenem + Vancomycin | 10 (1.3%) | 6 (2.8%) | 16 (1.6%) | 0.128 |
| Others | 215 (27.7%) | 48 (22.5%) | 263 (26.6%) | 0.137 |